ID,Source,PAID,Summary,Phenotype,Genotype,Recommendation,Avoid,Alternate,Dosing,Gene,Drug,GeneID,DrugID
1,DPWG,PA166184612,Annotation of DPWG Guideline for thioguanine and NUDT15,,,<p>Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>,0,1,1,NUDT15,thioguanine,0,0
2,DPWG,PA166265202,Annotation of DPWG Guideline for paclitaxel and CYP3A4,,,<p>There are currently no recommendations for paclitaxel dosing based on CYP3A4 genotypes.</p>,0,0,0,CYP3A4,paclitaxel,0,0
3,DPWG,PA166182816,Annotation of DPWG Guideline for bisoprolol and CYP2D6,,,<p>There are currently no dosing recommendations for bisoprolol based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,bisoprolol,0,0
4,DPWG,PA166104986,Annotation of DPWG Guideline for tolbutamide and CYP2C9,,,<p>There are currently no dosing recommendations for tolbutamide based on <em>CYP2C9</em> genotype.</p>,0,0,0,CYP2C9,tolbutamide,0,0
5,RNPGx,PA166422141,Annotation of RNPGx Guideline for abacavir and HLA-B,,,<p>The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines and requires mandatory HLA testing prior to prescribing abacavir and abacavir is contraindicated in patients where the HLA-B*57:01 is present.</p>,0,1,0,HLA-B,abacavir,0,0
6,DPWG,PA166104969,Annotation of DPWG Guideline for flecainide and CYP2D6,,,<p>Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.</p>,0,1,1,CYP2D6,flecainide,0,0
7,DPWG,PA166182841,Annotation of DPWG Guideline for warfarin and VKORC1,,,<p>Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) should be given 60% of the standard initial dose of warfarin. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There are no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).</p>,0,0,1,VKORC1,warfarin,0,0
8,DPWG,PA166264901,Annotation of DPWG Guideline for methylphenidate and COMT,,,<p>There are currently no dosing recommendations for methylphenidate based on COMT genotype.</p>,0,0,0,COMT,methylphenidate,0,0
9,CPIC,PA166273401,"Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and CYP3A4, CYP3A5, HMGCR",,,"<p>There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.</p>",0,0,0,CYP3A4; CYP3A5; HMGCR,atorvastatin; fluvastatin; lovastatin; pitavastatin; pravastatin; rosuvastatin; simvastatin,0,0
10,DPWG,PA166104990,Annotation of DPWG Guideline for voriconazole and CYP2C19,,,"<p>Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.</p>",0,0,1,CYP2C19,voriconazole,0,0
11,CPIC,PA166105006,"Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6",,,"<p>The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2C19; CYP2D6,amitriptyline,0,0
12,DPWG,PA166363221,Annotation of DPWG Guideline for rosuvastatin and SLCO1B1,,,"<p>Keep the rosuvastatin dose as low as possible (e.g. by adding ezetimibe) for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</p>",0,0,1,SLCO1B1,rosuvastatin,0,0
13,DPWG,PA166104953,Annotation of DPWG Guideline for glyburide and CYP2C9,,,<p>There are currently no dosing recommendations for glibenclamide based on CYP2C9 genotype.</p>,0,0,0,CYP2C9,glyburide,0,0
14,CPIC,PA166288561,Annotation of CPIC Guideline for duloxetine and CYP2D6,,,<p>There are currently no recommendations for dosing of duloxetine based on CYP2D6 genotypes.</p>,0,0,0,CYP2D6,duloxetine,0,0
15,CPIC,PA166104945,"Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT",,,<p>Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are intermediate metabolizers of either <em>TPMT</em> or <em>NUDT15</em>. Start at 20-50% of target dose for patients who are intermediate metabolizers of both <em>TPMT</em> and <em>NUDT15</em>. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,1,NUDT15; TPMT,mercaptopurine,0,0
16,CPIC,PA166288541,Annotation of CPIC Guideline for fluoxetine and CYP2D6,,,<p>There are currently no recommendations for dosing of fluoxetine based on <em>CYP2D6</em>  genotypes.</p>,0,0,0,CYP2D6,fluoxetine,0,0
17,CPIC,PA166114461,Annotation of CPIC Guideline for ivacaftor and CFTR,,,"<p>Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain <em>CFTR</em> variants.  See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,0,CFTR,ivacaftor,0,0
18,CPIC,PA166104965,"Annotation of CPIC Guideline for thioguanine and NUDT15, TPMT",,,<p>Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are intermediate metabolizers of either <em>TPMT</em> or <em>NUDT15</em>. Start at 20-50% of target dose for patients who are intermediate metabolizers of both <em>TPMT</em> and <em>NUDT15</em>. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,1,NUDT15; TPMT,thioguanine,0,0
19,DPWG,PA166104973,Annotation of DPWG Guideline for oxycodone and CYP2D6,,,<p>There are currently no dosing recommendations for oxycodone based on CYP2D6 genotypes.</p>,0,0,0,CYP2D6,oxycodone,0,0
20,DPWG,PA166363201,Annotation of DPWG Guideline for pravastatin and SLCO1B1,,,<p>There are currently no recommendations for pravastatin dosing based on SLCO1B1 genotypes.</p>,0,0,0,SLCO1B1,pravastatin,0,0
21,DPWG,PA166182820,Annotation of DPWG Guideline for prasugrel and CYP2C19,,,<p>There are currently no dosing recommendations for prasugrel based on CYP2C19 genotypes.</p>,0,0,0,CYP2C19,prasugrel,0,0
22,CPIC,PA166127638,"Annotation of CPIC Guideline for citalopram, escitalopram and CYP2C19",,,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends to consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid, likely poor, and poor metabolizers. In case citalopram or escitalopram are clinically appropriate, dose alterations are recommended.</p>",0,1,1,CYP2C19,citalopram; escitalopram,0,0
23,CPIC,PA166288582,"Annotation of CPIC Guideline for desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and HTR2A",,,"<p>There are currently no recommendations for dosing of fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran  based on HTR2A genotypes.</p>",0,0,0,HTR2A,desvenlafaxine; duloxetine; fluoxetine; fluvoxamine; levomilnacipran; milnacipran; paroxetine; sertraline; venlafaxine; vilazodone; vortioxetine,0,0
24,CPIC,PA166219103,"Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",,,"<p>The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</p>",0,0,1,CYP2C19,lansoprazole; omeprazole; pantoprazole,0,0
25,CPIC,PA166104949,"Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1",,,"<p>The updated guideline for pharmacogenetics-guided warfarin dosing is published by the <em>Clinical Pharmacogenetics Implementation Consortium</em>.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from <em>CYP2C9</em>, <em>VKORC1</em>, <em>CYP4F2</em>, and rs12777823.</p>",0,0,1,CYP2C9; CYP4F2; VKORC1,warfarin,0,0
26,RNPGx,PA166422161,Annotation of RNPGx Guideline for allopurinol and HLA-B,,,<p>The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines around testing for HLA-B*58:01 prior to prescription of allopurinol to avoid severe cutaneous adverse reactions (SCARs).</p>,0,1,0,HLA-B,allopurinol,0,0
27,CPIC,PA166104948,Annotation of CPIC Guideline for clopidogrel and CYP2C19,,,<p>The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)</p>,0,1,0,CYP2C19,clopidogrel,0,0
28,DPWG,PA166264961,Annotation of DPWG Guideline for allopurinol and ABCG2,,,"<p>Patients with the GT or TT genotypes at <a href=""/variant/PA166156544"">rs2231142</a> should be given an increased dose of allopurinol.</p>",0,0,1,ABCG2,allopurinol,0,0
29,CPIC,PA166127639,"Annotation of CPIC Guideline for sertraline and CYP2B6, CYP2C19",,,<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.</p>,0,1,1,CYP2B6; CYP2C19,sertraline,0,0
30,DPWG,PA166182821,Annotation of DPWG Guideline for sertraline and CYP2D6,,,<p>There are currently no dosing recommendations for sertraline based on CYP2D6 genotypes.</p>,0,0,0,CYP2D6,sertraline,0,0
31,CPIC,PA166228022,"Annotation of CPIC Guideline for methadone, oxycodone and COMT, CYP2D6, OPRM1",,,"<p>There are currently no recommendations for dosing of methadone or oxycodone based on <em>CYP2D6</em>, <em>OPRM1</em> or <em>COMT</em> genotypes.</p>",0,0,0,COMT; CYP2D6; OPRM1,methadone; oxycodone,0,0
32,CPIC,PA166262661,"Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, simvastatin and ABCG2",,,"<p>There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin and simvastatin dosing based on ABCG2 genotypes.</p>",0,0,0,ABCG2,atorvastatin; fluvastatin; lovastatin; pitavastatin; pravastatin; simvastatin,0,0
33,DPWG,PA166104972,Annotation of DPWG Guideline for imipramine and CYP2D6,,,"<p>CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>",0,1,1,CYP2D6,imipramine,0,0
34,CPIC,PA166161537,Annotation of CPIC Guideline for voriconazole and CYP2C19,,,"<p>The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.</p>",0,1,1,CYP2C19,voriconazole,0,0
35,DPWG,PA166104964,Annotation of DPWG Guideline for clomipramine and CYP2D6,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM) metabolizer, and ultrarapid (UM) metabolizer or to avoid clomipramine in PM and UM.</p>",0,1,1,CYP2D6,clomipramine,0,0
36,CPIC,PA166104933,"Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT",,,<p>Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are intermediate metabolizers of either <em>TPMT</em> or <em>NUDT15</em>. Start at 20-50% of target dose for patients who are intermediate metabolizers of both <em>TPMT</em> and <em>NUDT15</em>. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,1,NUDT15; TPMT,azathioprine,0,0
37,DPWG,PA166104944,Annotation of DPWG Guideline for tegafur and DPYD,,,"<p>Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>",0,1,1,DPYD,tegafur,0,0
38,DPWG,PA166104952,Annotation of DPWG Guideline for mercaptopurine and TPMT,,,<p>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>,0,1,1,TPMT,mercaptopurine,0,0
39,CPIC,PA166181885,Annotation of CPIC Guideline for atomoxetine and CYP2D6,,,"<p>The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,0,1,CYP2D6,atomoxetine,0,0
40,CPIC,PA166105007,"Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6",,,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2C19; CYP2D6,clomipramine,0,0
41,DPWG,PA166104991,Annotation of DPWG Guideline for abacavir and HLA-B,,,<p>Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are &quot;HLA-B*57:01-positive&quot;).</p>,0,1,0,HLA-B,abacavir,0,0
42,DPWG,PA166104987,Annotation of DPWG Guideline for lansoprazole and CYP2C19,,,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.</p>",0,0,1,CYP2C19,lansoprazole,0,0
43,DPWG,PA166104968,Annotation of DPWG Guideline for venlafaxine and CYP2D6,,,"<p>For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), therapy adjustment is not required or beneficial for this phenotype-drug combination.</p>",0,1,1,CYP2D6,venlafaxine,0,0
44,CPIC,PA166128738,Annotation of CPIC Guideline for atazanavir and UGT1A1,,,"<p>The CPIC dosing guideline recommends considering advising individuals who carry two decreased function <em>UGT1A1</em> alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function <em>UGT1A1</em> alleles, respectively. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,0,UGT1A1,atazanavir,0,0
45,DPWG,PA166182817,"Annotation of DPWG Guideline for citalopram, escitalopram and CYP2D6",,,<p>There are currently no dosing recommendations for citalopram/escitalopram based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,citalopram; escitalopram,0,0
46,DPWG,PA166184613,Annotation of DPWG Guideline for mercaptopurine and NUDT15,,,<p>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>,0,1,1,NUDT15,mercaptopurine,0,0
47,CPIC,PA166229081,"Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, streptomycin, tobramycin and MT-RNR1",,,<p>Administration of aminoglycoside antibiotics should be avoided in patients carrying certain <em>MT-RNR1</em> variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,0,MT-RNR1,amikacin; dibekacin; gentamicin; kanamycin; neomycin; netilmicin; paromomycin; plazomicin; ribostamycin; streptomycin; tobramycin,0,0
48,RNPGx,PA166202781,"Annotation of RNPGx Guideline for methotrexate and ABCB1, MTHFR, SLC19A1, SLCO1B1",,,<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.</p>,0,0,0,ABCB1; MTHFR; SLC19A1; SLCO1B1,methotrexate,0,0
49,DPWG,PA166104934,Annotation of DPWG Guideline for azathioprine and TPMT,,,<p>Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>,0,1,1,TPMT,azathioprine,0,0
50,CPIC,PA166122806,"Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B",,,"<p>Phenytoin/fosphenytoin is contraindicated in individuals with the <em>HLA-B*15:02</em> variant allele (&quot;<em>HLA-B*15:02</em>-positive&quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the <em>CYP2C9</em> poor metabolizer phenotype or with a <em>CYP2C9</em> activity score of 1 may require reduced doses of phenytoin/fosphenytoin.</p>",0,1,1,CYP2C9; HLA-B,fosphenytoin; phenytoin,0,0
51,DPWG,PA166104963,Annotation of DPWG Guideline for capecitabine and DPYD,,,"<p>An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>",0,1,1,DPYD,capecitabine,0,0
52,CPIC,PA166109594,Annotation of CPIC Guideline for capecitabine and DPYD,,,"<p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require a &gt;50% dose reduction. This guideline has been updated online since publication in 2017, and is in the process of being updated again based on a complete evidence review.</p>",0,1,1,DPYD,capecitabine,0,0
53,DPWG,PA166104975,Annotation of DPWG Guideline for escitalopram and CYP2C19,,,<p>The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.</p>,0,1,1,CYP2C19,escitalopram,0,0
54,DPWG,PA166184527,Annotation of DPWG Guideline for brexpiprazole and CYP2D6,,,<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the normal dose of brexpiprazole for poor metabolizers of CYP2D6.</p>,0,0,1,CYP2D6,brexpiprazole,0,0
55,CPIC,PA166341321,Annotation of CPIC Guideline for metoprolol and CYP2D6,,,"<p>Patients who are CYP2D6 poor metabolizers should initiate metoprolol therapy at the lowest recommended starting dose and carefully titrate upwards to clinical effect or guideline-recommended dose. Alternatively, a different beta-blocker may be selected. There is no recommendation for CYP2D6 ultrarapid metabolizers.</p>",0,1,0,CYP2D6,metoprolol,0,0
56,DPWG,PA166104959,Annotation of DPWG Guideline for tramadol and CYP2D6,,,"<p>Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects.</p>",0,1,1,CYP2D6,tramadol,0,0
57,CPIC,PA166262261,Annotation of CPIC Guideline for pitavastatin and SLCO1B1,,,<p>Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.</p>,0,1,1,SLCO1B1,pitavastatin,0,0
58,CPIC,PA166228121,Annotation of CPIC Guideline for hydrocodone and CYP2D6,,,"<p>CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.</p> <p>There is insufficient evidence to provide a dosing recommendation for hydrocodone in CYP2D6 ultrarapid metabolizers.</p>",0,0,0,CYP2D6,hydrocodone,0,0
59,CPIC,PA166416341,Annotation of CPIC Guideline for hydralazine and NAT2,,,"<p>Consider a starting total daily dose of hydralazine of at least 75 mg. for patients who are NAT2 rapid metabolizers and NAT2 intermediate metabolizers and titrate up to 300 mg as tolerated. For patients who are NAT2 poor metabolizers, initiate therapy at a total daily dose of hydralazine of 40 to 75 mg and carefully titrate upwards; use caution with total daily hydralazine doses of 200 mg or more.</p>",0,0,1,NAT2,hydralazine,0,0
60,DPWG,PA166184614,Annotation of DPWG Guideline for azathioprine and NUDT15,,,<p>Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>,0,1,1,NUDT15,azathioprine,0,0
61,DPWG,PA166265341,Annotation of DPWG Guideline for lamotrigine and HLA-B,,,"<p>Avoid lamotrigine in patients with HLA-B*15:02 if an alternative is available. If avoidance is not possible, advise to report any rash immediately.</p>",0,1,0,HLA-B,lamotrigine,0,0
62,CPIC,PA166228101,Annotation of CPIC Guideline for tramadol and CYP2D6,,,<p>Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.</p>,0,1,0,CYP2D6,tramadol,0,0
63,DPWG,PA166182810,Annotation of DPWG Guideline for flucloxacillin and HLA-B,,,"<p>Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*57:01.</p>",0,1,0,HLA-B,flucloxacillin,0,0
64,DPWG,PA166104938,Annotation of DPWG Guideline for acenocoumarol and VKORC1,,,<p>Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) should be given 50% of the standard initial dose of acenocoumarol and undergo more frequent INR monitoring. There are no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).</p>,0,0,1,VKORC1,acenocoumarol,0,0
65,RNPGx,PA166202801,Annotation of RNPGx Guideline for tamoxifen and CYP2D6,,,<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that there is no recommendation for genotyping CYP2D6 in all patients starting a tamoxifen regimen.</p>,0,0,0,CYP2D6,tamoxifen,0,0
66,DPWG,PA166104980,Annotation of DPWG Guideline for sertraline and CYP2C19,,,"<p>Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.</p>",0,0,1,CYP2C19,sertraline,0,0
67,CPIC,PA166191841,"Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9",,,"<p>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</p>",0,1,1,CYP2C9,celecoxib; flurbiprofen; ibuprofen; lornoxicam,0,0
68,CPIC,PA166104996,Annotation of CPIC Guideline for codeine and CYP2D6,,,<p>Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.</p>,0,1,0,CYP2D6,codeine,0,0
69,DPWG,PA166104979,Annotation of DPWG Guideline for acenocoumarol and CYP2C9,,,<p>There are currently no recommendations for acenocoumarol dosing based on CYP2C9 genotypes.</p>,0,0,0,CYP2C9,acenocoumarol,0,0
70,CPIC,PA166105000,"Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6",,,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2C19; CYP2D6,doxepin,0,0
71,CPIC,PA166262241,Annotation of CPIC Guideline for lovastatin and SLCO1B1,,,"<p>Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to &lt;20mg/day.</p>",0,1,1,SLCO1B1,lovastatin,0,0
72,CPIC,PA166345801,Annotation of CPIC Guideline for methadone and CYP2B6,,,<p>CPIC does not currently provide CYP2B6 genotype-based prescribing recommendations for methadone.</p>,0,0,0,CYP2B6,methadone,0,0
73,DPWG,PA166264881,Annotation of DPWG Guideline for phenytoin and HLA-B,,,<p>Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.</p>,0,1,0,HLA-B,phenytoin,0,0
74,CPIC,PA166220321,"Annotation of CPIC Guideline for esomeprazole, rabeprazole and CYP2C19",,,<p>The CPIC Dosing Guideline for <em>CYP2C19</em> and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of <em>CYP2C19</em> genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.</p>,0,0,0,CYP2C19,esomeprazole; rabeprazole,0,0
75,DPWG,PA166104943,Annotation of DPWG Guideline for risperidone and CYP2D6,,,<p>The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.</p>,0,1,1,CYP2D6,risperidone,0,0
76,DPWG,PA166104942,Annotation of DPWG Guideline for duloxetine and CYP2D6,,,<p>There are currently no dosing recommendations for duloxetine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,duloxetine,0,0
77,DPWG,PA166104954,Annotation of DPWG Guideline for imipramine and CYP2C19,,,"<p>CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>",0,1,1,CYP2C19,imipramine,0,0
78,DPWG,PA166265141,Annotation of DPWG Guideline for allopurinol and HLA-B,,,<p>Individuals with the HLA-B*58:01 allele should be given an alternative drug or undergo induction of allopurinol tolerance.</p>,0,1,1,HLA-B,allopurinol,0,0
79,DPWG,PA166182807,Annotation of DPWG Guideline for ticagrelor and CYP2C19,,,<p>There are currently no dosing recommendations for ticagrelor based on CYP2C19 genotypes.</p>,0,0,0,CYP2C19,ticagrelor,0,0
80,CPIC,PA166124619,Annotation of CPIC Guideline for tacrolimus and CYP3A5,,,"<p>The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.</p>",0,0,1,CYP3A5,tacrolimus,0,0
81,CPIC,PA166105001,"Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6",,,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2C19; CYP2D6,trimipramine,0,0
82,CPIC,PA166104997,Annotation of CPIC Guideline for abacavir and HLA-B,,,"<p>In individuals with the HLA-B*57:01 variant allele (&quot;HLA-B*57:01-positive&quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>",0,1,0,HLA-B,abacavir,0,0
83,DPWG,PA166104978,Annotation of DPWG Guideline for glimepiride and CYP2C9,,,<p>There are currently no dosing recommendations for glimepiride based on CYP2C9 genotype.</p>,0,0,0,CYP2C9,glimepiride,0,0
84,DPWG,PA166104981,Annotation of DPWG Guideline for flupenthixol and CYP2D6,,,<p>There are currently no dosing recommendations for flupenthixol based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,flupenthixol,0,0
85,DPWG,PA166182846,Annotation of DPWG Guideline for efavirenz and CYP2B6,,,"<p>Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the CYP2B6 IM phenotype, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.</p>",0,0,1,CYP2B6,efavirenz,0,0
86,CPIC,PA166279621,Annotation of CPIC Guideline for primaquine and G6PD,,,"<p>Primaquine should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA) in most cases, with some exceptions for G6PD deficient patients without CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.</p> <p>The G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.</p>",0,1,0,G6PD,primaquine,0,0
87,CPIC,PA166341341,"Annotation of CPIC Guideline for acebutolol, betaxolol, bisoprolol, carvedilol, nebivolol, propranolol and CYP2D6",,,"<p>There are currently no recommendations for dosing of acebutolol, betaxolol, bisoprolol, carvedilol, nebivolol or propranolol based on CYP2D6 genotypes.</p>",0,0,0,CYP2D6,acebutolol; betaxolol; bisoprolol; carvedilol; nebivolol; propranolol,0,0
88,DPWG,PA166182811,Annotation of DPWG Guideline for disopyramide and CYP2D6,,,<p>There are currently no dosing recommendations for disopyramide based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,disopyramide,0,0
89,DPWG,PA166104939,Annotation of DPWG Guideline for fluorouracil and DPYD,,,"<p>An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>",0,1,1,DPYD,fluorouracil,0,0
90,CPIC,PA166262221,Annotation of CPIC Guideline for atorvastatin and SLCO1B1,,,<p>Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.</p>,0,1,1,SLCO1B1,atorvastatin,0,0
91,DPWG,PA166211021,Annotation of DPWG Guideline for siponimod and CYP2C9,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for <em>CYP2C9</em> *1/*3, *2/*3 genotypes or CYP2C9 intermediate metabolizer (not including *2 and *3) and to avoid siponimod for the <em>CYP2C9</em> *3/*3 genotype or CYP2C9 poor metabolizer (two alleles with no/decreased enzyme activity, of which at least one other than *2 or *3).</p>",0,1,1,CYP2C9,siponimod,0,0
92,CPIC,PA166110235,"Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",,,"<p>IFNL3 (IL28B) variation (<a href=""/variant/PA166155468"">rs12979860</a>) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (<a href=""/variant/PA166155468"">rs12979860</a> CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (<a href=""/variant/PA166155468"">rs12979860</a> CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</p>",0,0,0,IFNL3,peginterferon alfa-2a; peginterferon alfa-2b; ribavirin,0,0
93,DPWG,PA166104958,Annotation of DPWG Guideline for pantoprazole and CYP2C19,,,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.</p>",0,0,1,CYP2C19,pantoprazole,0,0
94,DPWG,PA166184526,Annotation of DPWG Guideline for amitriptyline and CYP2C19,,,<p>There are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.</p>,0,0,0,CYP2C19,amitriptyline,0,0
95,DPWG,PA166104974,Annotation of DPWG Guideline for carvedilol and CYP2D6,,,<p>There are currently no dosing recommendations for carvedilol based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,carvedilol,0,0
96,DPWG,PA166265161,Annotation of DPWG Guideline for carbamazepine and HLA-A,,,<p>Consider an alternative drug to carbamazepine in patients with the HLA-A*3101 allele.</p>,0,1,0,HLA-A,carbamazepine,0,0
97,DPWG,PA166104962,Annotation of DPWG Guideline for propafenone and CYP2D6,,,"<p>Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.</p>",0,1,1,CYP2D6,propafenone,0,0
98,RNPGx,PA166202621,"Annotation of RNPGx Guideline for acenocoumarol, fluindione, warfarin and CYP2C9, VKORC1",,,<p>Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.</p>,0,1,1,CYP2C9; VKORC1,acenocoumarol; fluindione; warfarin,0,0
99,DPWG,PA166104935,Annotation of DPWG Guideline for clozapine and CYP2D6,,,<p>There are currently no dosing recommendations for clozapine based on CYP2D6 genotypes.</p>,0,0,0,CYP2D6,clozapine,0,0
100,CPIC,PA166279481,"Annotation of CPIC Guideline for chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mesalazine, moxifloxacin, nicorandil, nitrofurazone, probenecid, quinacrine, sodium nitrate, sulfacetamide, tolazamide, trametinib and G6PD",,,"<p>There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.</p>",0,0,0,G6PD,chlorpropamide; dabrafenib; gliclazide; glimepiride; glipizide; mesalazine; moxifloxacin; nicorandil; nitrofurazone; probenecid; quinacrine; sodium nitrate; sulfacetamide; tolazamide; trametinib,0,0
101,CPIC,PA166303941,"Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",,,"<p>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,0,CACNA1S; RYR1,desflurane; enflurane; halothane; isoflurane; methoxyflurane; sevoflurane; succinylcholine,0,0
102,DPWG,PA166411701,Annotation of DPWG Guideline for atazanavir and UGT1A1,,,"<p>For patients who are UGT1A1 *28/*28, avoidance of atazanavir is recommended if there is a suitable alternative.</p>",0,1,0,UGT1A1,atazanavir,0,0
103,CPIC,PA166288601,"Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone, vortioxetine and SLC6A4",,,"<p>There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on <em>SLC6A4</em> genotypes.</p>",0,0,0,SLC6A4,citalopram; desvenlafaxine; duloxetine; escitalopram; fluoxetine; fluvoxamine; levomilnacipran; milnacipran; paroxetine; sertraline; venlafaxine; vilazodone; vortioxetine,0,0
104,CPIC,PA166122687,Annotation of CPIC Guideline for tegafur and DPYD,,,"<p><strong>As of the <a rel=""noopener noreferrer"" href=""https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729.pdf"" target=""_blank"">November 2017 update</a> of CPIC guidelines regarding fluoropyrimidine dosing, there are no longer dosing recommendations for tegafur based on <em>DPYD</em>  genotype. This is due to limited evidence regarding the impact of <em>DPYD</em> variants on tegafur toxicity risk. The guidelines currently only apply to 5-fluorouracil and capecitabine dosing.</strong></p>",0,0,0,DPYD,tegafur,0,0
105,DPWG,PA166182808,Annotation of DPWG Guideline for methylphenidate and CYP2D6,,,<p>There are currently no dosing recommendations for methylphenidate based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,methylphenidate,0,0
106,DPWG,PA166265162,Annotation of DPWG Guideline for carbamazepine and HLA-B,,,<p>Consider an alternative drug to carbamazepine in patients with the HLA-B*15:02 or HLA-B*15:11 alleles.</p>,0,1,0,HLA-B,carbamazepine,0,0
107,DPWG,PA166104977,Annotation of DPWG Guideline for citalopram and CYP2C19,,,<p>The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.</p>,0,0,1,CYP2C19,citalopram,0,0
108,CPIC,PA166104998,Annotation of CPIC Guideline for nortriptyline and CYP2D6,,,"<p>The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2D6,nortriptyline,0,0
109,DPWG,PA166104961,Annotation of DPWG Guideline for nortriptyline and CYP2D6,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended.</p>",0,1,1,CYP2D6,nortriptyline,0,0
110,DPWG,PA166104941,Annotation of DPWG Guideline for moclobemide and CYP2C19,,,<p>No action is needed for this gene-drug interaction.</p>,0,0,0,CYP2C19,moclobemide,0,0
111,RNPGx,PA166202481,"Annotation of RNPGx Guideline for tacrolimus and CYP3A4, CYP3A5",,,"<p>Testing for the <em>CYP3A5*3</em> and <em>CYP3A4*22</em> alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.</p>",0,0,1,CYP3A4; CYP3A5,tacrolimus,0,0
112,RNPGx,PA166127626,Annotation of RNPGx Guideline for irinotecan and UGT1A1,,,"<p>A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of <em>UGT1A1*28</em> genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the <em>UGT1A1*28/*28</em> genotype, and that high-dose irinotecan (&gt;=240 mg/m2) only be prescribed to patients with the <em>UGT1A1*1/*1</em> genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs.</p>",0,0,1,UGT1A1,irinotecan,0,0
113,RNPGx,PA166422201,"Annotation of RNPGx Guideline for carbamazepine, oxcarbazepine and HLA-A, HLA-B",,,<p>The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has guidance about carbamazepine and oxcarbazepine toxicity and HLA-B*15:02 and HLA-A*31:01.</p>,0,0,0,HLA-A; HLA-B,carbamazepine; oxcarbazepine,0,0
114,DPWG,PA166418081,Annotation of DPWG Guideline for mavacamten and CYP2C19,,,<p>The Dutch Pharmacogenetics Working Group Guideline for mavacamten recommends a lower dose for CYP2C19 poor metabolizers and to avoid mavacamten in CYP2C19 poor metabolizers with strong CYP3A4 inhibitor as co-medication.</p>,0,1,1,CYP2C19,mavacamten,0,0
115,DPWG,PA166104957,Annotation of DPWG Guideline for omeprazole and CYP2C19,,,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.</p>",0,0,1,CYP2C19,omeprazole,0,0
116,DPWG,PA166184529,Annotation of DPWG Guideline for doxepin and CYP2C19,,,<p>There are currently no dosing recommendations for doxepin based on CYP2C19 genotype.</p>,0,0,0,CYP2C19,doxepin,0,0
117,CPIC,PA166105002,Annotation of CPIC Guideline for desipramine and CYP2D6,,,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2D6,desipramine,0,0
118,DPWG,PA166104994,Annotation of DPWG Guideline for doxepin and CYP2D6,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.</p>",0,1,1,CYP2D6,doxepin,0,0
119,DPWG,PA166182845,Annotation of DPWG Guideline for fluvastatin and SLCO1B1,,,<p>There are currently no recommendations for fluvastatin dosing based on SLCO1B1 genotypes.</p>,0,0,0,SLCO1B1,fluvastatin,0,0
120,DPWG,PA166104982,Annotation of DPWG Guideline for amitriptyline and CYP2D6,,,<p>The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.</p>,0,1,1,CYP2D6,amitriptyline,0,0
121,DPWG,PA166182813,Annotation of DPWG Guideline for fluvoxamine and CYP2D6,,,<p>There are currently no dosing recommendations for fluvoxamine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,fluvoxamine,0,0
122,DPWG,PA166182844,Annotation of DPWG Guideline for simvastatin and SLCO1B1,,,"<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>",0,1,1,SLCO1B1,simvastatin,0,0
123,DPWG,PA166104983,Annotation of DPWG Guideline for tacrolimus and CYP3A5,,,<p>Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.</p>,0,0,1,CYP3A5,tacrolimus,0,0
124,DPWG,PA166182852,Annotation of DPWG Guideline for fluoxetine and CYP2D6,,,<p>There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,fluoxetine,0,0
125,DPWG,PA166104995,Annotation of DPWG Guideline for metoprolol and CYP2D6,,,"<p>For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.</p>",0,1,1,CYP2D6,metoprolol,0,0
126,CPIC,PA166105003,Annotation of CPIC Guideline for allopurinol and HLA-B,,,<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>,0,1,0,HLA-B,allopurinol,0,0
127,DPWG,PA166182805,Annotation of DPWG Guideline for mirtazapine and CYP2C19,,,<p>There are currently no dosing recommendations for mirtazapine based on CYP2C19 genotypes.</p>,0,0,0,CYP2C19,mirtazapine,0,0
128,DPWG,PA166184528,Annotation of DPWG Guideline for clomipramine and CYP2C19,,,<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.</p>,0,1,0,CYP2C19,clomipramine,0,0
129,DPWG,PA166104956,Annotation of DPWG Guideline for clopidogrel and CYP2C19,,,"<p>Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.</p>",0,1,1,CYP2C19,clopidogrel,0,0
130,CPIC,PA166262281,Annotation of CPIC Guideline for pravastatin and SLCO1B1,,,<p>Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.</p>,0,1,1,SLCO1B1,pravastatin,0,0
131,DPWG,PA166104940,Annotation of DPWG Guideline for phenprocoumon and VKORC1,,,<p>Patients with the VKORC1 rs9923231 TT genotype (-1639 AA genotype) is recommended to be given 50% of the standard initial dose of phenprocoumon and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 rs9923231 CT genotype (-1639 AG genotype).</p>,0,0,1,VKORC1,phenprocoumon,0,0
132,DPWG,PA166104937,Annotation of DPWG Guideline for aripiprazole and CYP2D6,,,<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.</p>,0,0,1,CYP2D6,aripiprazole,0,0
133,DPWG,PA166104960,Annotation of DPWG Guideline for thioguanine and TPMT,,,<p>Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>,0,1,1,TPMT,thioguanine,0,0
134,CPIC,PA166341524,"Annotation of CPIC Guideline for carvedilol, labetalol, nadolol, pindolol, propranolol, sotalol and ADRB2",,,"<p>There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.</p>",0,0,0,ADRB2,carvedilol; labetalol; nadolol; pindolol; propranolol; sotalol,0,0
135,DPWG,PA166104976,Annotation of DPWG Guideline for paroxetine and CYP2D6,,,<p>Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.</p>,0,1,0,CYP2D6,paroxetine,0,0
136,CPIC,PA166104999,"Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6",,,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2C19; CYP2D6,imipramine,0,0
137,DPWG,PA166182809,Annotation of DPWG Guideline for gefitinib and CYP2D6,,,<p>There are currently no dosing recommendations for gefitinib based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,gefitinib,0,0
138,DPWG,PA166265421,Annotation of DPWG Guideline for quetiapine and CYP3A4,,,"<p>Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.</p> <p><em><strong>ClinPGx uses CYP3A4 allele nomenclature as defined by <a rel=""noopener noreferrer"" href=""https://www.pharmvar.org/"" target=""_blank"">PharmVar</a>, while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the <a href=""/page/dpwgMapping"">DPWG curation page</a>.</strong></em></p>",0,1,1,CYP3A4,quetiapine,0,0
139,CPIC,PA166122686,Annotation of CPIC Guideline for fluorouracil and DPYD,,,"<p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require a &gt;50% dose reduction. This guideline has been updated online since publication in 2017, and is in the process of being updated again based on a complete evidence review.</p>",0,1,1,DPYD,fluorouracil,0,0
140,CPIC,PA166119846,"Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",,,"<p>High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a <em>G6PD</em> variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.</p> <p>The G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.</p>",0,1,0,G6PD,dapsone; methylene blue; pegloticase; rasburicase; tafenoquine; toluidine blue,0,0
141,CPIC,PA166227941,"Annotation of CPIC Guideline for alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, morphine, naltrexone, remifentanil, sufentanil, tramadol and COMT, OPRM1",,,"<p>There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on <em>OPRM1</em> or <em>COMT</em> genotypes.</p>",0,0,0,COMT; OPRM1,alfentanil; buprenorphine; codeine; fentanyl; hydrocodone; hydromorphone; levomethadone; morphine; naltrexone; remifentanil; sufentanil; tramadol,0,0
142,CPIC,PA166222201,"Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipyrone, indomethacin, lumiracoxib, nabumetone, naproxen and CYP2C9",,,"<p>There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.</p>",0,0,0,CYP2C9,aceclofenac; aspirin; diclofenac; dipyrone; indomethacin; lumiracoxib; nabumetone; naproxen,0,0
143,DPWG,PA166104947,Annotation of DPWG Guideline for ribavirin and HLA-B,,,<p>There are no dosing recommendations for ribavirin in HLA-B*44 positive patients at this time.</p>,0,0,0,HLA-B,ribavirin,0,0
144,CPIC,PA166161955,Annotation of CPIC Guideline for tropisetron and CYP2D6,,,<p>The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,0,CYP2D6,tropisetron,0,0
145,CPIC,PA166127636,Annotation of CPIC Guideline for paroxetine and CYP2D6,,,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers. For CYP2D6 poor metabolizers, consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose.</p>",0,1,1,CYP2D6,paroxetine,0,0
146,DPWG,PA166264981,Annotation of DPWG Guideline for folic acid and MTHFR,,,<p>There are currently no recommendations for folic acid dosing based on MTHFR rs1801133 genotypes.</p>,0,0,0,MTHFR,folic acid,0,0
147,CPIC,PA166192341,Annotation of CPIC Guideline for tenoxicam and CYP2C9,,,<p>The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</p>,0,1,0,CYP2C9,tenoxicam,0,0
148,DPWG,PA166265001,Annotation of DPWG Guideline for methotrexate and MTHFR,,,<p>There are currently no recommendations for methotrexate dosing based on MTHFR rs1801133 genotypes.</p>,0,0,0,MTHFR,methotrexate,0,0
149,DPWG,PA166104951,Annotation of DPWG Guideline for irinotecan and UGT1A1,,,"<p>Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.</p>",0,0,1,UGT1A1,irinotecan,0,0
150,CPIC,PA166182603,Annotation of CPIC Guideline for efavirenz and CYP2B6,,,<p>Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.</p>,0,0,1,CYP2B6,efavirenz,0,0
151,DPWG,PA166105004,Annotation of DPWG Guideline for phenprocoumon and CYP2C9,,,<p>There are currently no recommendations for phenprocoumon dosing based on CYP2C9 genotypes.</p>,0,0,0,CYP2C9,phenprocoumon,0,0
152,DPWG,PA166182855,Annotation of DPWG Guideline for sotalol and CYP2D6,,,<p>There are currently no dosing recommendations for sotalol based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,sotalol,0,0
153,DPWG,PA166104992,Annotation of DPWG Guideline for zuclopenthixol and CYP2D6,,,"<p>For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose. For ultrarapid metabolizers, if the effectiveness is insufficient a dose increase not exceeding 1.5x normal dose is suggested.</p>",0,0,1,CYP2D6,zuclopenthixol,0,0
154,CPIC,PA166176068,Annotation of CPIC Guideline for tamoxifen and CYP2D6,,,"<p>The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy. The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>",0,1,1,CYP2D6,tamoxifen,0,0
155,DPWG,PA166265241,Annotation of DPWG Guideline for clozapine and CYP1A2,,,<p>There is no gene-drug interaction between CYP1A2 and clozapine.</p>,0,0,0,CYP1A2,clozapine,0,0
156,DPWG,PA166182843,Annotation of DPWG Guideline for atorvastatin and SLCO1B1,,,"<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</p>",0,1,1,SLCO1B1,atorvastatin,0,0
157,CPIC,PA166262341,"Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1",,,"<p>CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.</p>",0,1,1,CYP2C9; SLCO1B1,fluvastatin,0,0
158,DPWG,PA166104984,Annotation of DPWG Guideline for phenytoin and CYP2C9,,,<p>Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.</p>,0,0,1,CYP2C9,phenytoin,0,0
159,DPWG,PA166182814,Annotation of DPWG Guideline for fluvoxamine and CYP2C19,,,<p>There are currently no dosing recommendations for fluvoxamine based on CYP2C19 genotypes.</p>,0,0,0,CYP2C19,fluvoxamine,0,0
160,RNPGx,PA166202501,Annotation of RNPGx Guideline for clopidogrel and CYP2C19,,,"<p>Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor).</p>",0,1,0,CYP2C19,clopidogrel,0,0
161,CPIC,PA166279741,"Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol, chloroquine, ciprofloxacin, dimercaprol, doxorubicin, furazolidone, glyburide, hydroxychloroquine, mafenide, nalidixic acid, norfloxacin, ofloxacin, phenazopyridine, quinine, sulfadiazine, sulfamethazine, sulfamethoxazole, sulfamethoxazole / trimethoprim, sulfanilamide, sulfasalazine, sulfisoxazole, tolbutamide, vitamin c, Vitamin K and analogues and G6PD",,,"<p>There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, <strong>CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs</strong>.</p>",0,0,0,G6PD,aminosalicylic acid; chloramphenicol; chloroquine; ciprofloxacin; dimercaprol; doxorubicin; furazolidone; glyburide; hydroxychloroquine; mafenide; nalidixic acid; norfloxacin; ofloxacin; phenazopyridine; quinine; sulfadiazine; sulfamethazine; sulfamethoxazole; sulfamethoxazole / trimethoprim; sulfanilamide; sulfasalazine; sulfisoxazole; tolbutamide; vitamin c; Vitamin K and analogues,0,0
162,RNPGx,PA166202521,Annotation of RNPGx Guideline for azathioprine and TPMT,,,"<p>Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.</p>",0,1,1,TPMT,azathioprine,0,0
163,CPIC,PA166222181,"Annotation of CPIC Guideline for diclofenac, ibuprofen and CYP2C8",,,<p>There are currently no recommendations for NSAIDs dosing based on CYP2C8 genotypes.</p>,0,0,0,CYP2C8,diclofenac; ibuprofen,0,0
164,CPIC,PA166176623,Annotation of CPIC Guideline for oxcarbazepine and HLA-B,,,<p>The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of <em>HLA-B*15:02</em> due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).</p>,0,1,0,HLA-B,oxcarbazepine,0,0
165,DPWG,PA166182822,Annotation of DPWG Guideline for atenolol and CYP2D6,,,<p>There are currently no dosing recommendations for atenolol based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,atenolol,0,0
166,CPIC,PA166105008,"Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B",,,"<p>The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either <em>HLA-B*15:02</em> or <em>HLA-A*31:01</em> due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, <em>HLA-A*31:01</em> is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).</p>",0,1,0,HLA-A; HLA-B,carbamazepine,0,0
167,DPWG,PA166104971,Annotation of DPWG Guideline for gliclazide and CYP2C9,,,<p>There are currently no dosing recommendations for gliclazide based on CYP2C9 genotype.</p>,0,0,0,CYP2C9,gliclazide,0,0
168,DPWG,PA166104967,Annotation of DPWG Guideline for mirtazapine and CYP2D6,,,<p>There are currently no dosing recommendations for mirtazapine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,mirtazapine,0,0
169,DPWG,PA166104988,Annotation of DPWG Guideline for haloperidol and CYP2D6,,,<p>The recommendation for CYP2D6 poor metabolizers is to use 60% of the normal dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the normal dose or to choose an alternative to haloperidol.</p>,0,1,1,CYP2D6,haloperidol,0,0
170,RNPGx,PA166202761,Annotation of RNPGx Guideline for mercaptopurine and TPMT,,,<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.</p>,0,0,0,TPMT,mercaptopurine,0,0
171,DPWG,PA166182818,Annotation of DPWG Guideline for clonidine and CYP2D6,,,<p>There are currently no dosing recommendations for clonidine based on CYP2D6 genotype and DPWG suggest clonidine as possible alternative for atomoxetine in variant CYP2D6 metabolisers.</p>,0,0,0,CYP2D6,clonidine,0,0
172,DPWG,PA166104931,Annotation of DPWG Guideline for esomeprazole and CYP2C19,,,<p>No action is needed for this gene-drug interaction.</p>,0,0,0,CYP2C19,esomeprazole,0,0
173,DPWG,PA166182819,Annotation of DPWG Guideline for pimozide and CYP2D6,,,<p>Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.</p>,0,0,1,CYP2D6,pimozide,0,0
174,DPWG,PA166222801,Annotation of DPWG Guideline for flucytosine and DPYD,,,<p>The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.</p>,0,1,0,DPYD,flucytosine,0,0
175,DPWG,PA166104966,Annotation of DPWG Guideline for tamoxifen and CYP2D6,,,"<p>For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use.</p>",0,1,1,CYP2D6,tamoxifen,0,0
176,DPWG,PA166104989,Annotation of DPWG Guideline for atomoxetine and CYP2D6,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to side effects in CYP2D6 poor metabolizers.</p>",0,1,1,CYP2D6,atomoxetine,0,0
177,CPIC,PA166192321,Annotation of CPIC Guideline for piroxicam and CYP2C9,,,<p>The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</p>,0,1,0,CYP2C9,piroxicam,0,0
178,CPIC,PA166341522,"Annotation of CPIC Guideline for acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, sotalol and ADRA2C, ADRB1, GRK4, GRK5",,,"<p>There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.</p>",0,0,0,ADRA2C; ADRB1; GRK4; GRK5,acebutolol; atenolol; betaxolol; bisoprolol; carvedilol; esmolol; labetalol; metoprolol; nadolol; nebivolol; pindolol; propranolol; sotalol,0,0
179,DPWG,PA166104970,Annotation of DPWG Guideline for codeine and CYP2D6,,,"<p>The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration.</p>",0,1,1,CYP2D6,codeine,0,0
180,CPIC,PA166219301,Annotation of CPIC Guideline for dexlansoprazole and CYP2C19,,,<p>The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</p>,0,0,1,CYP2C19,dexlansoprazole,0,0
181,RNPGx,PA166202721,"Annotation of RNPGx Guideline for capecitabine, fluorouracil and DPYD",,,"<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.</p>",0,1,1,DPYD,capecitabine; fluorouracil,0,0
182,RNPGx,PA166202561,"Annotation of RNPGx Guideline for hmg coa reductase inhibitors, simvastatin and SLCO1B1",,,"<p>Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.</p>",0,1,1,SLCO1B1,HMG-CoA reductase inhibitors; simvastatin,0,0
183,DPWG,PA166182823,Annotation of DPWG Guideline for eliglustat and CYP2D6,,,"<p>The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for renal and hepatic impairment.</p>",0,1,1,CYP2D6,eliglustat,0,0
184,CPIC,PA166262321,"Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1",,,"<p>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose &gt;20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.</p>",0,1,1,ABCG2; SLCO1B1,rosuvastatin,0,0
185,CPIC,PA166288201,Annotation of CPIC Guideline for venlafaxine and CYP2D6,,,<p>The CPIC Dosing Guideline for venlafaxine recommends to consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6 for CYP2D6 poor metabolizers.</p>,0,1,0,CYP2D6,venlafaxine,0,0
186,CPIC,PA166288581,"Annotation of CPIC Guideline for citalopram, escitalopram and HTR2A",,,<p>There are currently no recommendations for dosing of escitalopram and citalopram based on <em>HTR2A</em> genotypes.</p>,0,0,0,HTR2A,citalopram; escitalopram,0,0
187,DPWG,PA166265221,Annotation of DPWG Guideline for olanzapine and CYP1A2,,,<p>There are currently no recommendations for olanzapine dosing based on CYP1A2 genotypes.</p>,0,0,0,CYP1A2,olanzapine,0,0
188,DPWG,PA166265201,Annotation of DPWG Guideline for oxcarbazepine and HLA-B,,,<p>Oxcarbazepine should be avoided if an alternative is available in patients with the HLA-B*15:02 allele.</p>,0,1,0,HLA-B,oxcarbazepine,0,0
189,RNPGx,PA166360361,Annotation of RNPGx Guideline for mavacamten and CYP2C19,,,"<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) considers the genotyping of CYP2C19*2 and *3 as essential for mavacamten, which is in line with the EMA label testing recommendation and dosing adjustments of mavacamten for poor metabolizers. There is also a review of CYP2C19*17 and other CYP2C variants and CYP3A4*20 and *22 and CYP3A5*3, *6 and *7.</p>",0,0,1,CYP2C19,mavacamten,0,0
190,DPWG,PA166182815,Annotation of DPWG Guideline for amiodarone and CYP2D6,,,<p>There are currently no dosing recommendations for amiodarone based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,amiodarone,0,0
191,DPWG,PA166182842,Annotation of DPWG Guideline for warfarin and CYP2C9,,,"<p>Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT.</p>",0,0,1,CYP2C9,warfarin,0,0
192,DPWG,PA166104985,Annotation of DPWG Guideline for rabeprazole and CYP2C19,,,<p>No action is needed for this gene-drug interaction.</p>,0,0,0,CYP2C19,rabeprazole,0,0
193,DPWG,PA166182854,Annotation of DPWG Guideline for quetiapine and CYP2D6,,,<p>There are currently no dosing recommendations for quetiapine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,quetiapine,0,0
194,CPIC,PA166279721,Annotation of CPIC Guideline for nitrofurantoin and G6PD,,,"<p>Nitrofurantoin should be use with caution in G6PD deficient patients without chronic non-spherocytic hemolytic anemia (CNSHA) and completely avoided by G6PD deficient patients with CNSHA. In patients with a <em>G6PD</em> variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.</p> <p>The G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.</p>",0,1,0,G6PD,nitrofurantoin,0,0
195,CPIC,PA166105005,Annotation of CPIC Guideline for simvastatin and SLCO1B1,,,"<p>Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to &lt;20mg/day.</p>",0,1,1,SLCO1B1,simvastatin,0,0
196,CPIC,PA166288221,Annotation of CPIC Guideline for vortioxetine and CYP2D6,,,"<p>The CPIC Dosing Guideline for vortioxetine recommends for CYP2D6 ultrarapid metabolizers to select alternative drug not predominantly metabolized by CYP2D6. For poor metabolizer, initiate 50% of starting dose and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.</p>",0,1,1,CYP2D6,vortioxetine,0,0
197,DPWG,PA166182803,Annotation of DPWG Guideline for quinidine and CYP2D6,,,<p>There are currently no dosing recommendations for quinidine based on CYP2D6 genotypes.</p>,0,0,0,CYP2D6,quinidine,0,0
198,RNPGx,PA166202701,"Annotation of RNPGx Guideline for antidepressants and CYP2C19, CYP2D6",,,"<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.</p>",0,1,1,CYP2C19; CYP2D6,antidepressants,0,0
199,CPIC,PA166279561,Annotation of CPIC Guideline for aspirin and G6PD,,,"<p>There is no reason to avoid aspirin at doses of ≤1g/day in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), aspirin ≤1g/day should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. CPIC gives a 'no recommendation' for the use of G6PD genotype for prescribing aspirin at doses &gt;1g/day. In summary, <strong>CPIC either does not provide, or recommend changing, prescribing actions based on G6PD genotype for aspirin at any dose.</strong></p>",0,0,0,G6PD,aspirin,0,0
200,CPIC,PA166161954,Annotation of CPIC Guideline for ondansetron and CYP2D6,,,<p>The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.</p>,0,1,0,CYP2D6,ondansetron,0,0
201,CPIC,PA166127637,Annotation of CPIC Guideline for fluvoxamine and CYP2D6,,,<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and slower titration schedule or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.</p>,0,1,1,CYP2D6,fluvoxamine,0,0
202,CPIC,PA166192301,Annotation of CPIC Guideline for meloxicam and CYP2C9,,,"<p>The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</p>",0,1,1,CYP2C9,meloxicam,0,0
203,RNPGx,PA166422181,Annotation of RNPGx Guideline for tebentafusp and HLA-A,,,<p>The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) requires testing for HLA-A*02:01 to select patients with metastatic uveal melanoma suitable for treatment with tebentafusp.</p>,0,1,0,HLA-A,tebentafusp,0,0
204,DPWG,PA166104946,Annotation of DPWG Guideline for olanzapine and CYP2D6,,,<p>There are currently no dosing recommendations for olanzapine based on CYP2D6 genotype.</p>,0,0,0,CYP2D6,olanzapine,0,0
